$JAZZ insider trading
Over the last 12 months, Jazz Pharmaceuticals insiders reported no purchases and 37 sales totaling $88.7M across SEC Form 4 filings. 49% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $88.7M 37 events
- Events · 12m
- 37 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 49% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Decision | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionarytax on vesting | 68,808 | $235.95 | $16.2M | -16.1% | 4 tranches |
| Nov 4, 2026 | Carr PatriciaSVP, Chief Accounting Officer · O | ▼ Sale | Discretionaryopen market | 1,413 | $231.36 | $327K | -17.8% | 2 tranches |
| Nov 3, 2026 | GALA RENEE DPresident & CEO · O·D | ▼ Sale | Non-discretionary10b5-1 plan | 1,000 | $225.37 | $225K | -0.7% | — |
| Nov 2, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $215.84 | $1.3M | -1.7% | — |
| Oct 6, 2026 | GALA RENEE DPresident & CEO · O·D | ▼ Sale | Non-discretionary10b5-1 plan | 2,000 | $236.4 | $473K | -1.4% | — |
| Oct 1, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $230.33 | $1.4M | -1.7% | — |
| Sep 10, 2026 | Patil Neena MEVP & Chief Legal Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,200 | $240.94 | $289K | -2.5% | — |
| Sep 8, 2026 | GALA RENEE DPresident & CEO · O | ▼ Sale | Non-discretionary10b5-1 plan | 2,000 | $243.03 | $486K | -1.4% | — |
| Sep 1, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $250.13 | $1.5M | -1.7% | — |
| Aug 27, 2026 | Iannone RobertEVP, Global Head of R&D & CMO · O | ▼ Sale | Non-discretionary10b5-1 plan | 76,921 | $249.7 | $19.2M | -53.9% | 6 tranches |
| Aug 3, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $252.98 | $1.5M | -1.6% | — |
| Jul 1, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $240.47 | $1.4M | -1.6% | — |
| Jun 15, 2026 | Smith Mark DouglasD | ▼ Sale | Non-discretionary10b5-1 plan | 1,157 | $230.55 | $267K | -10.7% | — |
| Jun 10, 2026 | Patil Neena MEVP & Chief Legal Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,200 | $231.83 | $278K | -2.3% | — |
| Jun 1, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $235.12 | $1.4M | -1.6% | — |
| May 28, 2026 | Patil Neena MEVP & Chief Legal Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,192 | $236.97 | $282K | -2.2% | — |
| May 28, 2026 | Pearce SamanthaEVP, Chief Commercial Officer · O | ▼ Sale | Discretionaryexercise and sell | 6,907 | $235.41 | $1.6M | -12.1% | — |
| May 22, 2026 | Winningham Rick ED | ▼ Sale | Unclearcover or choice | 2,741 | $241.57 | $662K | -22.3% | — |
| May 22, 2026 | McSharry Heather AnnD | ▼ Sale | Discretionaryopen market | 2,000 | $241 | $482K | -9.8% | — |
| May 1, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $203.33 | $1.2M | -1.6% | — |
| Apr 1, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $190.5 | $1.1M | -1.5% | 3 tranches |
| Mar 9, 2026 | Carr PatriciaSVP, Chief Accounting Officer · O | ▼ Sale | Discretionaryopen market | 1,287 | $182.94 | $235K | -16.5% | — |
| Mar 3, 2026 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $186.44 | $1.1M | -1.5% | 3 tranches |
| Feb 27, 2026 | Carr PatriciaSVP, Chief Accounting Officer · O | ▼ Sale | Discretionaryopen market | 2,370 | $192.6 | $456K | -20.4% | 2 tranches |
| Feb 27, 2026 | RIEDEL NORBERT GD | ▼ Sale | Discretionaryexercise and sell | 3,415 | $192 | $656K | -32.7% | — |
| Feb 26, 2026 | Henderson Mary ElizabethSVP, Technical Operations · O | ▼ Sale | Non-discretionarytax on vesting | 5,343 | $194.49 | $1.0M | -15.7% | — |
| Feb 26, 2026 | Patil Neena MEVP & Chief Legal Officer · O | ▼ Sale | Discretionaryopen market | 55,600 | $191.56 | $10.7M | -48.6% | 11 tranches |
| Jan 16, 2026 | Patil Neena MEVP & Chief Legal Officer · O | ▽ Sale to issuer | — | 3,275 | $171.16 | $561K | -5.8% | — |
| Dec 9, 2025 | Henderson Mary ElizabethSVP, Technical Operations · O | ▼ Sale | Discretionaryopen market | 2,238 | $169.51 | $379K | -10.3% | — |
| Dec 5, 2025 | Carr PatriciaSVP, Chief Accounting Officer · O | ▼ Sale | Discretionaryexercise and sell | 4,660 | $171.2 | $798K | -39.9% | 2 tranches |
| Nov 26, 2025 | COZADD BRUCE CD | ▼ Sale | Discretionaryexercise and sell | 77,500 | $177.81 | $13.8M | -16.5% | 4 tranches |
| Nov 20, 2025 | McSharry Heather AnnD | ▼ Sale | Discretionaryexercise and sell | 3,415 | $177.78 | $607K | -14.3% | — |
| Nov 19, 2025 | Henderson Mary ElizabethSVP, Technical Operations · O | ▽ Sale to issuer | — | 1,331 | $180.4 | $240K | -5.8% | — |
| Nov 18, 2025 | Carr PatriciaSVP, Chief Accounting Officer · O | ▼ Sale | Discretionaryexercise and sell | 5,319 | $182.06 | $968K | -43.1% | 2 tranches |
| Nov 18, 2025 | Winningham Rick ED | ▼ Sale | Discretionaryopen market | 5,500 | $180.86 | $995K | -38.2% | — |
| Nov 18, 2025 | COZADD BRUCE CD | ▼ Sale | Discretionaryopen market | 18,000 | $181.09 | $3.3M | -4.4% | 4 tranches |
| Nov 17, 2025 | Iannone RobertEVP, Global Head of R&D & CMO · O | ▼ Sale | Non-discretionary10b5-1 plan | 7,159 | $168.26 | $1.2M | -9% | — |
| Oct 3, 2025 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 5,500 | $137.01 | $754K | -1.3% | 2 tranches |
| Sep 2, 2025 | COZADD BRUCE CD | ▼ Sale | Non-discretionary10b5-1 plan | 6,000 | $128.62 | $772K | -1.4% | 2 tranches |
Every $JAZZ filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Jazz Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $JAZZ feed.